CoChat

Smoking‐cessation therapy using varenicline: the cost‐utility of an additional 12‐week course of varenicline for the maintenance of smoking abstinence

Bolin, Kristian, Mörk, Ann‐Christin, Wilson, Koo · 2009 · Journal of Evaluation in Clinical Practice
Cited by 30

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Study objectives To evaluate the cost‐effectiveness of an additional 12‐week treatment with varenicline for abstainers who had successfully completed an initial 12‐week treatment. Design The Benefits of Smoking Cessation on Outcomes simulation model was used to simulate both direct and indirect effects of smoking cessation. All calculations were performed in 2003 Swedish prices. Setting Sweden in 2003. Patients or participants The modelled cohort consisted of 25% of adult smokers motivated to quit smoking (168 844 males and 208 737 females). The age and sex distributions of the cohort reflect that of the Swedish population in 2003. Interventions Smokers who had achieved abstinence for at least 7 days following 12‐week open‐label treatment with varenicline were randomized to receive an additional 12‐week treatment with either varenicline or placebo. Measurements and results The incremental costs per quality‐adjusted life‐year (QALY) gained, for abstainers who received an additional 12‐week varenicline treatment compared with only 12 weeks, were €7066 for men and €7108 for women, over a 50‐year time horizon. (1€ ≈ SEK 9.12). These estimates excluded indirect effects on production and consumption of increased survival. The corresponding incremental costs per QALY including indirect effects were €24 149 and €24 436, respectively. Sensitivity analysis indicated that the estimated cost‐utility ratios are robust, but relatively sensitive to treatment efficiency and intervention costs. Conclusions An additional 12‐week course of varenicline treatment, provided to abstainers after an initial 12‐week treatment, produces relatively low incremental cost‐utility ratios in the spectrum of life‐saving medical treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2753.2008.01045.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 30

Metadata

Authors
Bolin, K., Mörk, A., & Wilson, K.
Venue
Journal of Evaluation in Clinical Practice
Publisher
Wiley
Published
2009-05-26
Volume
15
Issue
3
Pages
478-485
ISSN
  • 1356-1294 (ISSN-L)
  • 1365-2753
OpenAlex
W2129810252
Cited by
30
References
6
FWCI
1.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Smoking‐cessation therapy using varenicline: the cost‐utility of an additional 12‐week course of varenicline for the maintenance of smoking abstinence. https://app.cochat.ai/papers/10.1111/j.1365-2753.2008.01045.x
The paper
Bolin, K., Mörk, A., & Wilson, K. (2009). Smoking‐cessation therapy using varenicline: the cost‐utility of an additional 12‐week course of varenicline for the maintenance of smoking abstinence. Journal of Evaluation in Clinical Practice. https://doi.org/10.1111/j.1365-2753.2008.01045.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.